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In patients with diabetes mellitus (DM), adequate glucose control is of major importance. When treatment schemes become more
complicated, proper self-management through intermittent self-measurement of blood glucose (SMBG), among others, becomes
crucial in achieving this goal. In the last decade, continuous glucose monitoring (CGM) has been on the rise, providing not only
intermittent information but also information on continuous glucose trends. ,e FreeStyle Libre (FSL) Flash CGM system is a
CGM system mainly used for patients with DM and is designed based on the same techniques as early CGMs. Compared with
earlier CGMs, the FSL is factory calibrated, has no automated readings or direct alarms, and is cheaper to use. Although less
accurate compared with the gold standard for SMBG, users report high satisfaction because it is easy to use and can help users
monitor glucose trends. ,e Flash Monitor Register in the Netherlands (FLARE-NL) study aims to assess the eﬀects of FSL Flash
CGM use in daily practice. ,e study has a before-after design, with each participant being his or her own control. Users will be
followed for at least 1 year. ,e endpoints include changes in HbA1c, frequency and severity of hypoglycemias, and quality of life.
In addition, the eﬀects of its use on work absenteeism rate, diabetes-related hospital admission rate, and daily functioning
(including sports performance) will be studied. Furthermore, cost-beneﬁt analysis based on the combination of registered
information within the health insurance data will be investigated. Ultimately, the data gathered in this study will help increase the
knowledge and skills of the use of the Flash CGM in daily practice and assess the ﬁnancial impact on the use of the Flash CGM
within the Dutch healthcare system.
1. Introduction
In individuals with diabetes mellitus (DM), it has been
unanimously accepted that the development of micro- and
macrovascular complications is linked to the duration and
severity of hyperglycemia [1]. However, besides hypergly-
cemia, the presence of ﬂuctuations in blood glucose con-
centrations (so-called “glycemic variability”) is also
associated with the risk of microvascular complications and
hypoglycemia with subsequent stress, anxiety, impaired
health, and reduced quality of life (QoL) [2, 3]. ,erefore,
eﬀorts are made to maintain blood glucose levels as close to
normal as possible, while minimizing glycemic variability
and, consequently, the risk of hypoglycemia.
At present, blood glucose concentrations are mainly
measured by applying a drop of blood to a chemically treated
“test strip,” which is then inserted into an electronic blood
glucose meter (BGM). In the last few decades, BGMs have
been supplemented and even supplanted by systems mea-
suring interstitial ﬂuid, aiming at “real-time” continuous
glucose measurements (rt-CGM) [4, 5] with and without
intelligent connection with an external insulin pump.
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However, measuring and assessing interstitial ﬂuid glucose
levels and translating such outcomes into results comparable
to capillary glucose concentrations have been a challenge
[6, 7].
In 2014, the FreeStyle Libre Flash Monitor (FSL-FM)
system [8] was introduced, which performs on partially
diﬀerent principles than earlier CGMs. ,e user must
proactively obtain the results by using a reader instead of
data being relayed automatically to a receiver. Furthermore,
the FSL-FM is calibrated during the fabrication process
instead of being calibrated daily by the patient and is meant
to be inserted in the upper arm only. According to the
manufacturer, no further individual calibration is needed,
not to mention that the patient does not have access to the
monitor to be able to do so. Use of the FSL-GM reduces, but
does not remove, the need for BGM.
In the light of the challenges to acquire reliable and
accurate data, our research group assessed the performance
of the FSL-FM by conducting an independent validation
study [9]. We demonstrated a high correlation between the
gold standard isotope dilution gas chromatograph-mass
spectrometer (ID-GCMS) and the capillary measurement
techniques used in our study (SMBG). ,e FSL-FM was less
accurate compared with the SMBG and also the gold
standard. Under normal circumstances, glucose levels on the
low end of the spectrum as shown by the FSL-FM are
generally lower than the results provided by other tech-
niques including the gold standard, while glucose levels on
the high end are generally recorded higher. Furthermore,
after a standardized meal, glucose levels assessed by the FSL-
FM rose slower compared with the results of all other tested
methods for glucose measurement.
Although the FSL-FM is less accurate in measuring
blood glucose levels compared with other methods, the
overall patient satisfaction with the FSL, both in individual
user experiences and in studies, is high. FSL users were better
informed of their glucose trends and levels and were more
conﬁdent in their decisions. Hence, from a user perspective,
this new device is very much appreciated because of its ease
of use, the possibility to see trends in glucose changes, and
the possibility to obtain 24-hour general information for the
last 14 days, provided the readings were performed at least
every 8 hours.
Despite the high patient satisfaction with the new sys-
tem, the Dutch health authorities and insurance companies
considered the scientiﬁc evidence and technical aspects of
the FSL-FM to be insuﬃcient to warrant widespread re-
imbursement. Furthermore, they considered the description
of speciﬁc target groups as being too diﬀuse. Hence, the
Flash Monitor Register in the Netherlands (FLARE-NL) was
established to answer these concerns. On the contrary, both
the Dutch diabetes patient organization (Diabetesvereniging
Nederland, DVN) and some Dutch healthcare providers
welcomed the FSL-FM as an adjunct to present glucose
measurement possibilities. ,e main arguments by both
groups are the individually reported improvements in QoL
and reduction in the users’ fear of unexpected hypoglycemia.
Furthermore, the ability to see trends is considered a major
positive asset by users.
,is before and after interventional study aimed to assess
the patient-oriented endpoints related to the use of the
FreeStyle Libre Flash response system (FSL-FM) in persons
with diabetes mellitus (Flash Monitor Register in the
Netherlands: FLARE-NL) in daily practice.
2. Materials and Methods
2.1. Aims. ,e register aimed to assess the eﬀects of the FSL-
FM on user-related endpoints.
Primary outcome measures are changes in hemoglobin
A1c (HbA1c), QoL using the 12-Item Short-Form Health
Survey (SF-12) [10] and the six-dimensional EuroQol in-
strument (EQ-6D) [11–13], the number of hypoglycemic
episodes, and the number of hospitalizations related to DM.
Secondary outcomes include changes in the number of
working days lost/days absent fromwork due to illness, daily
functioning (including sports performance), and results of
cost-eﬀectiveness and cost-beneﬁt analyses of combining
register and health insurance data.
We hypothesize that the use of the FSL-FM will improve
glycemic control (especially in those patients with the worst
metabolic control) and QoL; its eﬀects on diabetes-related
hospitalizations will probably be minimal. We expect a
decrease in work absenteeism rate and an increase in ex-
ercise activity, possibly related to increased self-conﬁdence.
2.2.Design. ,e register and the studies based on the register
information have an interventional design: patients with
DM will complete questionnaires before using the FSL-FM,
after six months of use, and after twelve months of use. ,e
total follow-up period will be 1 year.
2.3. Population. ,e intended study population consists of
adults (≥18 years) with both type 1 and type 2 DM who use
insulin. All patients will be required to be treated by a
hospital-based secondary care diabetes team, have health
insurance with Zilveren Kruis/Achmea (the largest health
insurance company in the Netherlands), and belong to one
or more of the target groups (see Table 1).
2.4.GroupSize Inclusion. No total group estimation through
power calculation has been performed since all patients who
fulﬁll the criteria described below will be included if con-
sidered ﬁt for participation. Nonetheless, since some esti-
mates can help support the drive to recruit enough
participants to detect signiﬁcant diﬀerences, a power cal-
culation was performed for target group 3 (“unable to reach
an HbA1c <65mmol/mol despite maximal eﬀorts”), for
whom the important primary outcome measure is the
change in HbA1c. ,erefore, the sample size was calculated
for HbA1c using Sample Power 3.0 for the calculation. Based
on a paired t-test, two-sided testing was carried out, with a
power of 90%. An estimated 10% reduction in HbA1c is
considered clinically relevant and feasible in this target
group. ,e correlation between the HbA1c at the start of the
study and the HbA1c at 6months was estimated at 0.80,
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resulting in a standard deviation of 8.854. ,e mean HbA1c
at the baseline was estimated at 64mmol/mol. A 10% re-
duction (6.4mmol/mol) would result in an HbA1c of
57.4mmol/mol after 6months of follow-up. ,e lowest
acceptable reduction of the HbA1c is 5% (3.2mmol/mol).
2.4.1. Hypotheses
H0: μΔ< 5% (3.2mmol/mol)
H1: μΔ≥ 5% (3.2mmol/mol), most preferably 10%
(6.4mmol/mol)
Sample size was calculated using parametric and non-
parametric analyses, yielding sample sizes of 83 and 92
participants, respectively.
2.5. Selection Procedure. ,e departments of internal medi-
cine and/or diabetes centers of all Dutch hospitals are asked to
include individuals based on the inclusion criteria as described
in Table 1. All these centers have been approached in writing,
and extensive information regarding the register has been
provided.,is information is also available in the register, and
the procedure is available on http://www.FSLregister.nl [14].
Each participating hospital will provide the data to a single
contact person appointed within the department of internal
medicine. ,is person is then considered responsible for
collecting the data in the center.
After providing the details requested for the register (see
Tables 2 and 3) and obtaining the informed consent of the
projected user, the patient creates his or her own proﬁle to
log in and is asked to complete three questionnaires on
the site at 0, 6, and 12months. ,ese questionnaires are the
SF-12 [15], the EQ-6D [16–18], and a newly created ques-
tionnaire from the DVN (see Addendum 1). Although the
latter questionnaire is not validated, we have included it
upon request from the DVN to allow an alternative approach
from the user perspective. Finally, patients will answer
questions regarding diabetes-related incidents in everyday
life. Table 4 shows an overview of the self-reported and
practitioner-reported data.
2.6. Economic Analysis. After ﬁnishing the 1-year actual
study, data gathered by the Diabetes Research Center at Isala
will be combined with data from the insurance company ZK
by a trusted third party to create an anonymized database to
allow analysis of the economic aspects of FSL use, initially
concentrating on the following healthcare costs:
(i) Overall costs
(ii) Hospital costs (with speciﬁc attention to admis-
sions related to diabetes mellitus) including out-
patient expenditure




(vii) Diabetes-related costs within these separate cost
groups
2.7. Ethical Considerations. ,e protocol was approved by
the Medical Ethical Committee of Isala. Furthermore, the
Medical Ethical Committee decided for a non-WMO lia-
bility status (METC 16.0346). Patients will participate after
informed consent is obtained, after which their e-mail ad-
dresses and contact details will be collected. Patients will be
asked to accept the electronic informed consent both for
permission to use the information for the study and for the
later use of this information to create an anonymized da-
tabase, combining registry data with health insurance data.
3. Discussion
,e possibilities to assess glucose levels with a variety of
methods have been increasing in the last few years, and the
trend will continue in the future. Some of these methods will
be based on probes and devices which either need to be
inserted or implanted (either intravascular or interstitial)
[10–13, 19–24], and some will be noninvasive, e.g., mea-
suring glucose through the skin by Raman spectroscopy
[25, 26], in lacrimal ﬂuids [27], and in sweat [28]. However,
Table 1: Inclusion criteria for target groups.
(1) Patients with “hypoglycemia unawareness” and moderate to severe hypoglycemic episodes after an average of six or more
measurements per day over the past year and despite intensive support from a diabetes team
(2) Patients with unexpected hypoglycemia after obtaining an average of six or more measurements per day over the past year and despite
intensive support from a diabetes team
(3) Patients treated with insulin who, despite maximal eﬀorts (frequent blood monitoring and proper lifestyle management) and intensive
support from the diabetes team, do not reach acceptable glycemic control, as evidenced by a mean HbA1c >64mmol/mol (8.0%) over the
year preceding the inclusion
(4) Patients who have an occupation whereby loss of sensation in the ﬁngers by frequent use of BGMs may lead to disability (e.g.,
musicians) and who are under other circumstances would be advised by the healthcare team to perform frequent blood glucose
measurements to better control their diabetes
(5) Patients who have an occupation whereby even rarely occurring hypoglycemic episodes would lead to a situation endangering
themselves and/or others (e.g., bus and lorry drivers, school teachers, and sports trainers).
(6) Patients who are already eligible for CGM according to Dutch regulations;
children with type 1 diabetes (up to 18 years);
pregnancy wish and pregnancy in diabetic individuals (type 1 and type 2);
adults with type 1 diabetes with poor metabolic control (HbA1c >64mmol/mol) for a longer period.
(7) Patients already using the FSL-FM at their own expense but fall into one of the categories described above
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it must be concluded that the farther the probe or device is
from the blood circulation, the larger the chance that the
accuracy of measurements will be lost.
Manufacturing a device with an accuracy comparable to
BGM when measuring glucose concentrations in the in-
terstitial ﬂuid and translating such concentrations into the
equivalent blood glucose concentrations is challenging, es-
pecially when no calibration is required by the manufacturer
or even possible, like that of the FSL-FM.
However, even in cases of less accuracy, user satisfaction
can be high, and use of a device like the FSL-FMmay lead to
improved metabolic control, characterized not only by a
(further) decrease in HbA1c but also by maintaining an
acceptable HbA1c level with less episodes of (severe)
hypoglycemia.
Furthermore, from a user perspective, the classical in-
dications for CGM use, like poor metabolic control and
(frequent) occurrence of episodes of relevant hypoglycemia,
might be too restrictive. In the Netherlands, use of medi-
cations like insulin, which is known to induce hypoglycemia
on occasion, may lead to job loss (e.g., when driving a bus or
a heavy lorry), which might be prevented when users show
their ability to better control their blood glucose levels.
Another reason to use FSL-GM includes being able to
properly participate in sports and exercise activities, which
leads not only to more user satisfaction but also to health
gain in the long term.
,e strength of the proposed approach lies in the inclusion
of a large group of patients from all over the Netherlands,
which may result in ﬁndings that are generalizable.
,e limitations of this approach are inherent to the study
design. Most of the results are reported by the participants
themselves. Since in due course they might proﬁt from
positive results of this study by portraying results more
Table 3: Follow-up data and measurements after 6 and 12months.
(i) Scores from EQ-6D and SF-12v2 questionnaires
(ii) HbA1c levels within the preceding 6months, to be reported both by the user and the healthcare professional
(iii) Any diabetes-related hospitalizations
(iv) Changes in presence of complications
(v) Self-reported number of diabetes-related hospitalizations in the previous year
(vi) Self-reported estimated/felt/measured hypoglycemias in three months before ﬁlling out questionnaires; speciﬁc categorization for
severe (grade III) hypoglycemia
(vii) Self-reported levels of working day losses or reduced functioning (including sports performance) due to dysregulation of DM
(viii) DVN questionnaire
(ix) Satisfaction from the use of FLS-FM
Table 4: Overview of self-report and practitioner-reported data.
Self-report Reported by practitioner
(i) HbA1c T6 and T12months (i) Target group
(ii) QoL using the 12-Item Short-FormHealth Survey
(SF-12) (ii) HbA1c T0, T6, and T12months
(iii) Six-dimensional EuroQol instrument (EQ-6D)
(iv) Questionnaire DVN
(v) ,e number of hypoglycemic episodes
(vi) ,e number of hospitalizations related to DM
(vii) Changes in the number of working days lost/
days absent from work due to illness
(viii) Daily functioning (including sports
performance)
Table 2: Required baseline data and measurements.
(i) Demographic data including type of DM (type 1 DM, type 2 DM, latent autoimmune diabetes, maturity-onset diabetes of the young, and
others)
(ii) Indication for participation
(iii) HbA1c levels of preceding year (last four measurements), to be reported by the health professional
(iv) Absence or presence of neuropathy, retinopathy, nephropathy, or macrovascular disease
(v) Frequency of SBGM
(vi) Scores of EQ-6D and SF-12v2 questionnaires
(vii) Self-reported number of diabetes-related hospitalizations in the previous year
(viii) Self-reported estimated/measured hypoglycemias 3months before the device is used; speciﬁc categorization for severe (grade III)
hypoglycemia (grade I (mild) symptoms with blood glucose <70mg/dL, grade II (minor) symptoms with blood glucose <56mg/dL, and
grade III (severe) symptoms with glucose <40mg/dL, requiring third-party assistance)
(ix) Self-reported levels of working day losses or reduced functioning (including sports performance) due to glucose variability
(x) DVN questionnaire
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favorably, this could introduce response bias. Nonetheless,
by starting this register from a patient/user perspective, we
havemade a choice to consider patient-oriented outcomes as
valid and acceptable.
An improvement in glycated hemoglobin can also mean
an increase in HbA1c for a person with “hypoglycemia
unawareness” and “unexpected hypoglycemia.” It might be
useful to relax, rather than reduce, the HbA1c target in an
attempt to diminish hypoglycemic incidents and possibly
regain hypoglycemia awareness. ,erefore, HbA1c changes
will be reported per target group. Causes of unexpected
hypoglycemia can also be hypoglycemic episodes during or
after exercise or in case of erratic gastric emptying.
Results from this register will aid in decision making in
terms of reimbursement not only in the Netherlands but also
hopefully in other countries as well.
4. Conclusion
In conclusion, the register for the FSL-FM in the Nether-
lands is important because it not only is based on HbA1c,
which is regarded as the sole or most important primary
endpoint by regulatory agencies and insurance companies,
but also emphasizes user-centered factors including health-
related QoL, changes in self-conﬁdence which may allow
users to explore their physical limits more fully, device user-
friendliness, and major societal aspects like work absen-
teeism and hospital admission rates. As such, we hope that
the more holistic approach used in this registry design will
become more common when assessing a device like the FSL-
FM, allowing reimbursement decisions to be made not only
based purely on medical arguments but also on other user-
centric metrics.
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